OS of patients treated with epigenetic therapy compared with patients treated with AI or other high-dose ara-C–containing regimens. Shown are OS rates of patients treated with epigenetic therapy (azacitidine vs decitabine) compared with that of patients treated with AI or other high-dose ara-C (HDAC)–containing regimens (A) and OS after failure of AI, azacitidine, or decitabine (B).